519 related articles for article (PubMed ID: 28414061)
1. Mechanistic correlates of clinical responses to omalizumab in the setting of oral immunotherapy for milk allergy.
Frischmeyer-Guerrerio PA; Masilamani M; Gu W; Brittain E; Wood R; Kim J; Nadeau K; Jarvinen KM; Grishin A; Lindblad R; Sampson HA
J Allergy Clin Immunol; 2017 Oct; 140(4):1043-1053.e8. PubMed ID: 28414061
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy.
Wood RA; Kim JS; Lindblad R; Nadeau K; Henning AK; Dawson P; Plaut M; Sampson HA
J Allergy Clin Immunol; 2016 Apr; 137(4):1103-1110.e11. PubMed ID: 26581915
[TBL] [Abstract][Full Text] [Related]
3. The safety and efficacy of sublingual and oral immunotherapy for milk allergy.
Keet CA; Frischmeyer-Guerrerio PA; Thyagarajan A; Schroeder JT; Hamilton RG; Boden S; Steele P; Driggers S; Burks AW; Wood RA
J Allergy Clin Immunol; 2012 Feb; 129(2):448-55, 455.e1-5. PubMed ID: 22130425
[TBL] [Abstract][Full Text] [Related]
4. Blocking antibodies induced by peanut oral and sublingual immunotherapy suppress basophil activation and are associated with sustained unresponsiveness.
Orgel K; Burk C; Smeekens J; Suber J; Hardy L; Guo R; Burks AW; Kulis M
Clin Exp Allergy; 2019 Apr; 49(4):461-470. PubMed ID: 30383313
[TBL] [Abstract][Full Text] [Related]
5. Successful Milk Oral Immunotherapy Promotes Generation of Casein-Specific CD137
Zhang Y; Li L; Genest G; Zhao W; Ke D; Bartolucci S; Pavey N; Al-Aubodah TA; Lejtenyi D; Torabi B; Ben-Shoshan M; Mazer B; Piccirillo CA
Front Immunol; 2021; 12():705615. PubMed ID: 34887847
[TBL] [Abstract][Full Text] [Related]
6. Oral Immunotherapy for Food Allergy.
Wood RA
J Investig Allergol Clin Immunol; 2017; 27(3):151-159. PubMed ID: 28102823
[TBL] [Abstract][Full Text] [Related]
7. Clinical aspects of oral immunotherapy for the treatment of allergies.
Yanagida N; Sato S; Ebisawa M
Semin Immunol; 2017 Apr; 30():45-51. PubMed ID: 28780220
[TBL] [Abstract][Full Text] [Related]
8. Predicting development of sustained unresponsiveness to milk oral immunotherapy using epitope-specific antibody binding profiles.
Suárez-Fariñas M; Suprun M; Chang HL; Gimenez G; Grishina G; Getts R; Nadeau K; Wood RA; Sampson HA
J Allergy Clin Immunol; 2019 Mar; 143(3):1038-1046. PubMed ID: 30528770
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Outcome of Peanut Oral Immunotherapy Facilitated Initially by Omalizumab.
Yee CSK; Albuhairi S; Noh E; El-Khoury K; Rezaei S; Abdel-Gadir A; Umetsu DT; Burke-Roberts E; LeBovidge J; Schneider L; Rachid R
J Allergy Clin Immunol Pract; 2019 Feb; 7(2):451-461.e7. PubMed ID: 30267889
[TBL] [Abstract][Full Text] [Related]
10. Sustained successful peanut oral immunotherapy associated with low basophil activation and peanut-specific IgE.
Tsai M; Mukai K; Chinthrajah RS; Nadeau KC; Galli SJ
J Allergy Clin Immunol; 2020 Mar; 145(3):885-896.e6. PubMed ID: 31805311
[TBL] [Abstract][Full Text] [Related]
11. The Use of Omalizumab in Food Oral Immunotherapy.
Labrosse R; Graham F; Des Roches A; Bégin P
Arch Immunol Ther Exp (Warsz); 2017 Jun; 65(3):189-199. PubMed ID: 27628022
[TBL] [Abstract][Full Text] [Related]
12. Early decrease in basophil sensitivity to Ara h 2 precedes sustained unresponsiveness after peanut oral immunotherapy.
Patil SU; Steinbrecher J; Calatroni A; Smith N; Ma A; Ruiter B; Virkud Y; Schneider M; Shreffler WG
J Allergy Clin Immunol; 2019 Nov; 144(5):1310-1319.e4. PubMed ID: 31377342
[TBL] [Abstract][Full Text] [Related]
13. Oral immunotherapy combined with omalizumab for high-risk cow's milk allergy: a randomized controlled trial.
Takahashi M; Soejima K; Taniuchi S; Hatano Y; Yamanouchi S; Ishikawa H; Irahara M; Sasaki Y; Kido H; Kaneko K
Sci Rep; 2017 Dec; 7(1):17453. PubMed ID: 29234055
[TBL] [Abstract][Full Text] [Related]
14. Identification of novel peptide biomarkers to predict safety and efficacy of cow's milk oral immunotherapy by peptide microarray.
Martínez-Botas J; Rodríguez-Álvarez M; Cerecedo I; Vlaicu C; Diéguez MC; Gómez-Coronado D; Fernández-Rivas M; de la Hoz B
Clin Exp Allergy; 2015 Jun; 45(6):1071-84. PubMed ID: 25772539
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy for cow's milk allergy.
Taniuchi S; Takahashi M; Soejima K; Hatano Y; Minami H
Hum Vaccin Immunother; 2017 Oct; 13(10):2443-2451. PubMed ID: 28825866
[TBL] [Abstract][Full Text] [Related]
16. Combining anti-IgE with oral immunotherapy.
Lin C; Lee IT; Sampath V; Dinakar C; DeKruyff RH; Schneider LC; Nadeau KC
Pediatr Allergy Immunol; 2017 Nov; 28(7):619-627. PubMed ID: 28782296
[TBL] [Abstract][Full Text] [Related]
17. Changes in passively-sensitized basophil activation to αS1-casein after oral immunotherapy.
Matsui T; Naito M; Tagami K; Tajima I; Teshigawara M; Makino A; Kitamura K; Takasato Y; Sugiura S; Yamada C; Izumi H; Tsuge I; Kondo Y; Ito K
Immun Inflamm Dis; 2020 Jun; 8(2):188-197. PubMed ID: 32125071
[TBL] [Abstract][Full Text] [Related]
18. Successful oral desensitization in children with cow's milk anaphylaxis: Clinical and laboratory evaluation up to nine-years follow-up.
Alves-Correia M; Gaspar Â; Borrego LM; Azevedo J; Martins C; Morais-Almeida M
Allergol Immunopathol (Madr); 2019; 47(2):133-140. PubMed ID: 30482599
[TBL] [Abstract][Full Text] [Related]
19. Omalizumab in IgE-Mediated Food Allergy: A Systematic Review and Meta-Analysis.
Zuberbier T; Wood RA; Bindslev-Jensen C; Fiocchi A; Chinthrajah RS; Worm M; Deschildre A; Fernandez-Rivas M; Santos AF; Jaumont X; Tassinari P
J Allergy Clin Immunol Pract; 2023 Apr; 11(4):1134-1146. PubMed ID: 36529441
[TBL] [Abstract][Full Text] [Related]
20. High IgE levels to α-lactalbumin, β-lactoglobulin and casein predict less successful cow's milk oral immunotherapy.
Kuitunen M; Englund H; Remes S; Movérare R; Pelkonen A; Borres MP; Mäkelä MJ
Allergy; 2015 Aug; 70(8):955-62. PubMed ID: 25951431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
